Clinical Trial

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-04-21; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2023-05-22
Trial Details
NCT Number NCT04858256
Lead Sponsor University of Michigan Rogel Cancer Center
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI), Hoosier Cancer Research Network, CTI BioPharma
Conditions T-Cell Neoplasm, Lymphoproliferative Disorders
Enrollment 100 participants
Start Date 2023-03-29
Primary Completion 2027-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-29